NewsRoom

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2011201020092008

2018 Archives

Dec 2, 2018
- Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients -
Nov 8, 2018
-- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End --
Nov 5, 2018
MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments
Aug 30, 2018
-Fiscal Year 2018 Highlighted by Progress Across All Four Clinical-stage Oncology Candidates; ME-401 Accelerated Approval Study to Start by Year-end 2018-
Jun 15, 2018
--Initiation of registration study for ME-401 in patients with relapsed or refractory follicular lymphoma expected before year-end--
Jun 4, 2018
-- ME-344 Mitochondrial Inhibitor in Combination with Avastin Demonstrates Inhibition of Tumor Proliferation in HER2 Negative Breast Cancer Patients --
May 31, 2018
-- Predefined Patient Retention Threshold Met: 10% Early Discontinuation Rate Due to Adverse Events Supports Expansion of Patient Enrollment --
May 9, 2018
Data readouts in three programs expected in the second calendar quarter of 2018
Feb 13, 2018
Interim data further support potential of ME-344 to reverse resistance to antiangiogenic therapy
Feb 8, 2018
Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA
 

rss